United States District Court, D. New Jersey.
In re GABAPENTIN PATENT LITIGATION
Pfizer Inc., Warner-Lambert Co., and G'f6decke Aktiengesellschaft, Plaintiffs. v. Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd, Defendants.
Nos. MDL NO. 13874(JCL), 00-2931(JCL), CIV.A.00-4168(JCL), CIV.A.00-4589(JCL)
Aug. 25, 2005.
Background: Holder of patent for drug gabapentin sued prospective manufacturers of generic version, claiming patent infringement. Prospective manufacturer brought motion for summary judgment of noninfringement of claims of patent based on use of certain adjuvants.
Holdings: The District Court, Lifland, J., held that:
claim excluded at least eight particular lactam-promoting adjuvants;
term "adjuvant" meant that subset of inactive ingredients that was intimately mixed with active
ingredient to form drug mixture; and (3) claim was directed at gabapentin and substances mixed intimately therewith.
John J. Francis, Jr., Drinker Biddle & Reath, Florham Park, NJ, David S. Copeland, Leora Ben-Ami, Stephen J. Elliott, Kaye Scholer, LLP, New York City, for Plaintiffs.
Allyn Zissel Lite, Lite, Depalma, Greenberg and Rivas, LCC, Arnold B. Calmann, Saiber, Schlesinger, Satz & Goldstein, LLC, Newark, NJ, Patrick J. Hughes, Connell Foley, LLP, Roseland, NJ, Neil S. Cartusciello, Mendham, NJ, for Defendants.
MEMORANDUM AND ORDER
LIFLAND, District Judge.